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Breast cancer suppressor BRCA2 is critical for main-
tenanceof genomic integrity and resistance to agents
that damage DNA or collapse replication forks,
presumably through homology-directed repair of
double-strand breaks (HDR). Using single-molecule
DNA fiber analysis, we show here that nascent
replication tracts created before fork stalling with
hydroxyurea are degraded in the absence of BRCA2
but are stable in wild-type cells. BRCA2 mutational
analysis reveals that a conserved C-terminal site
involved in stabilizing RAD51 filaments, but not in
loading RAD51 onto DNA, is essential for this fork
protection but dispensable for HDR. RAD51 filament
disruption in wild-type cells phenocopies BRCA2
deficiency. BRCA2 prevents chromosomal aberra-
tions on replication stalling, which are alleviated by
inhibition of MRE11, the nuclease responsible for
this form of fork instability. Thus, BRCA2 prevents
rather than repairs nucleolytic lesions at stalled
replication forks to maintain genomic integrity and
hence likely suppresses tumorigenesis through this
replication-specific function.
INTRODUCTION
BRCA2 is one of the two genes frequently found mutated in
hereditary breast cancers, and its mutation is also associated
with ovarian and pancreatic cancer in adults, as well as brain
and other tumors in children with Fanconi anemia (Gudmunds-
dottir and Ashworth, 2006;Moynahan and Jasin, 2010). Although
it may have other cellular functions, including during cell cycle
progression (Ayoub et al., 2009), the role of BRCA2 is best under-
stood during DNA double-strand break (DSB) repair by homolo-
gous recombination, also termed homology-directed repair(HDR) (Moynahan et al., 2001), where it mediates RAD51 nucle-
oprotein filament formation on single-stranded (ss) DNA (Jensen
et al., 2010).
Human BRCA2 has 8 conserved RAD51 interaction motifs
termed BRC repeats, which are essential for HDR (Moynahan
and Jasin, 2010). The importance of HDR for survival is reflected
in the observation that truncations of BRCA2 that include the
BRC repeats are lethal in mice during embryogenesis (Moyna-
han, 2002). In addition to the BRC repeats, a RAD51 interaction
site has been identified in the C-terminal 200 amino acids of
BRCA2 (C-ter), which is also conserved, but which is distinct in
sequence from the BRC repeats (Esashi et al., 2005). Whereas
BRCA2 truncations involving only the BRCA2 C-ter region
appear developmentally normal, they confer shorter life spans,
increased tumorigenesis, and hematopoietic dysfunction
(McAllister et al., 2002; Navarro et al., 2006; Donoho et al., 2003).
BRCA2 plays a key role in repairing DSBs arising during repli-
cation, which are repaired by HDR (Bryant et al., 2005; Lomono-
sov et al., 2003; Su et al., 2008). Although DSBs in principle can
be repaired via nonhomologous end-joining (NHEJ), HDR is
a preferred pathway during the S and G2 phases of the cell cycle
when homologous chromatids are available to template the
repair process (Moynahan and Jasin, 2010). DSB repair by either
pathway requires end-processing, for which the MRE11
nuclease is implicated (Mimitou and Symington, 2009). To this
end, MRE11 has endonuclease activity that promotes 50-30
resection of DNA ends critical for HDR, as well as 30-50 exonu-
clease activity (Williams et al., 2008), which may also trim DNA
ends for repair. Moreover, MRE11 is rapidly recruited to nuclear
foci at stalled forks on exposure to the replication poison
hydroxyurea (HU) (Wang et al., 2000).
Given the central function BRCA2 during HDR, it has been
presumed that BRCA2 is required during replication perturbation
due to its function in HDR (Budzowska and Kanaar, 2009; Nagar-
aju and Scully, 2007). Here we investigate at the molecular level
the role of BRCA2 when replication is perturbed in vivo. We find
that BRCA2 has a protective function during replication fork
stalling that is mechanistically distinct from repair via HDR.Cell 145, 529–542, May 13, 2011 ª2011 Elsevier Inc. 529
Figure 1. BRCA2 Protects Nascent DNA Strands at Stalled Replication Forks
(A) Schematic of single DNA fiber analysis. Green tracts, IdU; red tracts, CldU. Examples of various types of tracts are shown.
(B) IdU tract length distributions from DNA fibers from BRCA2-deficient (V-C8) and proficient (V-C8+BRCA2) hamster cells in the presence (replication stalling) or
absence (unperturbed replication) of HU. Sketch above delineates experimental design. Median tract lengths are given in parentheses here and in subsequent
figures. Inset, cumulative distributions. Error bars represent the standard error of the mean (SEM).
(C) IdU tracts in Brca2lex1/lex2 and wild-type mES cells, with and without HU.
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Specifically, BRCA2 prevents degradation of nascent strands at
stalled forks by MRE11. The RAD51 binding site within the
BRCA2 C-ter, which stabilizes RAD51 filaments, is necessary
for protection of stalled forks, but it is not required for DSB repair
via HDR, providing a separation of function between these two
processes. BRCA2 mutants with compromised fork protection
exhibit increased spontaneous and HU-induced chromosomal
aberrations that are alleviated by MRE11 inhibition. Thus, these
data reveal a critical role for BRCA2 in maintaining genomic
stability, and likely suppressing tumorigenesis, independent of
HDR.
RESULTS
BRCA2 Protects Nascent DNA Strands at Stalled
Replication Forks
To obtain a better understanding of BRCA20s role during DNA
replication, DNA fiber analysis was utilized to monitor replication
perturbation genome-wide at single-molecule resolution (Fig-
ure 1A). This procedure marks newly synthesized DNA strands
just before (green fluorescent IdU) and after (red fluorescent
CldU) exposure to HU, which transiently stalls replication by
causing an imbalance in the deoxyribonucleoside triphosphate
pool. Retention of the IdU label after HU treatment measures
the stability of stalled forks (S IdU) (Figure 1A).
In hamster cells expressing wild-type BRCA2 (V-C8+BRCA2),
the median IdU tract length is maintained intact with or without
HU treatment for 5 hr (9.73 and 9.77 mm respectively, p =
0.924, two-tailed Mann-Whitney test) (Figure 1B), indicating
that the integrity of stalled forks is not compromised during pro-
longed periods of replication stress. In contrast, nascent IdU
tracts substantially shorten in cells deficient for BRCA2 (V-C8)
(Wiegant et al., 2006) when replication forks are stalled
compared to unperturbed replication (5.44 and 9.06 mm, respec-
tively, p < 0.0001) (Figure 1B). As nascent IdU tracts are formed
before treatment with HU, the disappearance of IdU label occurs
during HU exposure. We confirmed that IdU shortening in
BRCA2-deficient cells occurs irrespective of the choice of the
replication poison by replacing HU with the chemotherapeutic
gemcitabine, a nucleoside analog that inhibits DNA elongation
(see Figure S1A available online). Thus, BRCA2 functions in
protecting nascent strands when replication forks are stalled.
To determine if the requirement for BRCA2 in protecting
stalled replication forks is common to other cell types, we exam-
ined Brca2lex1/lex2 mouse embryonic stem (mES) cells, which
express a C-terminal truncation of BRCA2 (Morimatsu et al.,
1998). As with V-C8 cells, IdU tracts shorten in Brca2lex1/lex2 cells
exposed to HU compared with unimpeded replication (4.76 and(D) IdU tracts in the BRCA2-deficient human CAPAN-1 cell line and a BRCA2 rev
(E) CldU tracts of replication after exposure to HU ormedia in V-C8 and V-C8+BRC
Figures S1D.
(F) DNA fiber images from CAPAN-1 cells treated with HU and labeled with CldU
(G) Gap lengths between IdU tracts before HU and CldU tracts after HU (yellow di
(H) Individual DNA fiber images from CAPAN-1 and C2-14 cells treated with HU
and CldU labels. The % of fibers with gaps between the IdU and CldU labels is giv
Figure S1F. See also Table S1 for detailed information on data sets and stat
See also Figure S1.6.79 mm, respectively; p < 0.0001), whereas the nascent tracts
remain intact in wild-type mES cells (Figure 1C and Figure S1B).
In addition, human CAPAN-1 cells, which express a similar
BRCA2 truncation as V-C8 cells (Goggins et al., 1996), are defec-
tive in maintaining nascent tracts compared with unimpeded
replication (5.41 mm and 9.53 mm, respectively; p < 0.0001) (Fig-
ure 1D and Figure S1C). Reversion of the BRCA2 mutation in the
CAPAN-1 cells by a nearby second-site mutation (C2-14 cells)
(Sakai et al., 2008) (Figure S1C) largely restores the protection
of the stalled replication forks (Figure 1D). These results indicate
that BRCA2 is required for the protection of stalled replication
forks in multiple mammalian cell lines.
Recovery after Replication Stalling in BRCA2-Deficient
Cells
Depletion of RAD51 has been reported to decrease replication
restart after HU (Petermann et al., 2010) and uncouple leading
and lagging-strands (Hashimoto et al., 2010). To address
whether replication recovery is affected when BRCA2 is absent,
CldU tract lengths formed after HU exposure were measured.
Replication is substantially slowed after HU treatment, but
similarly so in both control and BRCA2-deficient cells (5.93 and
5.67 mm, V-C8+BRCA2 and V-C8 after HU, respectively) (Fig-
ure 1E). In these experiments, the IdU and CldU labels are often
quite separated, indicating that forks stall only transiently with
HU in these hamster cells. Therefore, we assessed the frequency
of replication restart (IdU/CldU) when CldU was present during
HU. As with replication recovery after HU, we find no significant
difference between BRCA2-proficient and deficient hamster
cells (Figure S1D). Further, the frequency of new replication
tracts is also unaffected by BRCA2 status (Figure S1D).
Given that replication restart may be more stringently
controlled in human cells than rodent cells (Petermann et al.,
2010), we also assessed restart in CAPAN-1 and revertant cells.
Consistent with a more efficient block in human cells, IdU and
CdU tracts are more frequently joined when the CldU label is
added after HU exposure than they are in hamster cells. This
apparent replication restart (IdU/CldU) is not significantly
impaired under this condition with or without BRCA2 (Fig-
ure S1E), although we did observe a small increase in tracts
labeled only with IdU in CAPAN-1 cells (13% to 19%, p =
0.279; Figure S1E).
We noticed that most restart tracts have small gaps between
the IdU and CldU labels (Figure 1F, right), indicating limited
fork progression during exposure to HU. A larger portion of tracts
from CAPAN-1 C2-14 cells have gaps (77.5%) compared with
CAPAN-1 cells (66.5%), implying that the block to restart is
more efficient in the absence of BRCA2 (p = 0.0134) (Figure 1H).ertant of CAPAN-1 (C2-14), with and without HU.
A2 cells. Inset, cumulative distributions. Error bars represent the SEM. See also
either during HU (left panel) or after HU (right panel).
stribution) and CldU tract lengths during HU (red distribution) in CAPAN-1 cells.
and then labeled with CldU, marked to show the gap in label between the IdU
en for each cell line. Gap length frequency is shown for each cell line. See also
istical tests, including 95% confidence interval for cumulative distributions.
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Figure 2. Inhibition of MRE11 Alleviates Nucleolytic Degradation of Stalled Forks
(A and B) Preformed IdU tract lengths in V-C8 (A) and V-C8+BRCA2 (B) cells during different exposure times to HU. Inset, the rate of IdU tract length change
is 0.7 mm/hr, estimated to be 1.8 kb/hr.
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To examine transient replication restart during HU, we included
CldU during HU in a control experiment in CAPAN-1 cells and
found that 97% of forks continue to incorporate CldU label
even in the presence of HU (Figure 1F, left). Surprisingly, the
continuous CldU tracts formed during HU are substantially
longer than the gaps between the two labels in experiments
where the label is omitted during HU (compare 9.73 mm CldU
tract length during HU and 1.27 mmgap length during HUwithout
label) (Figure 1G). We interpret this data to reflect asymmetric
replication fork movement during HU, indicating leading and
lagging strand uncoupling (Figure S1F). We reasoned that gap
tract lengths can be used to assess the ability of both strands
to continue replication during HU. Gap lengths are smaller in
CAPAN-1 compared to CAPAN-1 C2-14 cells (p < 0.0001) (Fig-
ure 1H), providing evidence that BRCA2 can suppress uncou-
pling of the leading and lagging strands.
Nucleolytic Degradation of Stalled Forks Is Progressive
and Has Directionalities
To better understand the mechanism of replication tract short-
ening during fork stalling, we monitored the integrity of the
nascent strands by varying the exposure times to HU. Consistent
with nucleolytic degradation of the stalled forks, preformed
IdU tracts in V-C8 cells progressively shorten during HU (Fig-
ure 2A, inset, and Figure S2A), with a rate of 0.7 mm/hr, corre-
sponding to 1.8 kb/hr. By contrast, preformed IdU tracts in
cells with BRCA2 remain largely unchanged (Figure 2B and
Figure S2B).
To fine map the degradation, we consecutively labeled
nascent tracts with IdU and CldU for equal periods of time before
HU (Figure 2C). In unperturbed V-C8 cells, IdU and CldU tracts
are similar in length (CldU/IdU = 1.03) (Figure 2D). When chal-
lenged with HU, CldU tracts shorten whereas IdU tracts remain
intact (CldU/IdU = 0.65) (Figure 2D and Figure S2C), indicating
that the more recently synthesized DNA is degraded first.
Thus, leading strands are degraded 30-50, whereas lagging
strands are degraded 50-30 (Figure 2C). In contrast, the CldU/
IdU ratio in VC-8+BRCA2cells is1with orwithoutHU (Figure 2E
and Figure S2C). These results imply that BRCA2 protects
against degradation of stalled replication forks with opposite
directionalities for the leading and lagging strands.
MRE11 Is Responsible for Nascent Strand Shortening
at Stalled Forks
The slow kinetics of degradation (1.8 kb/hr) are reminiscent of
another controlled degradative process, that of DNA end resec-
tion (4 kb/hr in yeast) (Fishman-Lobell et al., 1992). We consid-
ered that MRE11, which possesses 30-50 exonuclease activity
and also promotes 50-30 end resection (Mimitou and Symington,
2009; Williams et al., 2008), could promote fork degradation in
the absence of BRCA2. To test this, we used mirin, a chemical
inhibitor of MRE11 nuclease activity (Dupre et al., 2008). With(C) Sketch of design and expected outcome of nuclease directionality test. Tick
(D and E) Distribution curves of the ratio of CldU/IdU tract lengths with or withou
(F) IdU tract lengths in V-C8 and V-C8+BRCA2 cells with or without HU in the pr
(G) IdU tract lengths in Brca2lex1/lex2mES cells after shRNA treatment directed aga
MRE11 knockdown. See also Figure S2.mirin, IdU tracts are similar in length irrespective of replication
stalling in both BRCA2-deficient and proficient cells (Figure 2F
and Figure S2D), suggesting that the MRE11 nuclease degrades
stalled forks in the absence of BRCA2. To exclude off-target
effects by the inhibitor, we expressed shRNA against MRE11
in Brca2lex1/lex2 cells (Figure 2G), which like mirin, substantially
protects the nascent tracts during HU (6.18 and 4.05 mm with
and without MRE11 knockdown, respectively; p < 0.0001) (Fig-
ure 2G). These results further implicate the MRE11 complex,
specifically its nuclease activity, in fork degradation in the
absence of BRCA2.
Replication Fork Protection Is Independent
of Canonical NHEJ and the HDR Protein RAD54
The KU heterodimer, a key component of canonical NHEJ, is
important in the protection of DNA ends from nucleolytic diges-
tion (Kass and Jasin, 2010). We tested whether loss of KU would
also lead to deprotection of DNA ends at stalled replication forks.
Nascent IdU tracts are maintained intact in Ku70/ mES cells
(Figure 3A), consistent with a specific role for KU at DSBs, but
not at stalled forks (Pierce et al., 2001).
We next examined whether protection of stalled forks is a
property of all HDR proteins. RAD54 acts during late steps of
HDR (Heyer et al., 2006), downstream of BRCA2-mediated
RAD51 nucleoprotein filament formation. Yet, RAD54 is not
evidently involved in fork protection, as Rad54/ mES cells
exhibit similar IdU tract lengths with or without HU (Figure 3B),
thus indicating that not all HDR components are required to
avoid fork degradation.
Domain Requirements for BRCA2 in Replication
Fork Protection
BRCA2 contains both protein and DNA interaction domains,
including several BRC repeats that bind RAD51, a DNA binding
domain (DBD) consisting of several DNA binding modules, and
a C-terminal site (C-ter) that also binds RAD51 (Figure 4A). Given
the multidomain structure of BRCA2, we sought to characterize
the domain requirements for replication fork stability.
V-C8 cells have two Brca2 alleles encoding proteins truncated
for the C-ter and DBD domain (Figure 4A) (Wiegant et al., 2006)
and are defective in both HDR (Saeki et al., 2006) and mainte-
nance of fork stability (Figure 1B). As BRCA2 could directly inhibit
degradation via protein-DNA interactions requiring the DBD
domain, we generated a V-C8 cell line stably expressing
a BRCA2 peptide missing the entire DBD domain (PIR2; Fig-
ure 4A), but which is proficient at HDR (Figure S3A) (Edwards
et al., 2008). No substantial difference in IdU tract lengths was
observed with or without HU (9.69 and 8.74 mm, respectively)
(Figure 4B and Figure S3B). Thus, the BRCA2 DBD is not
required for the protection of stalled replication forks, indicating
that it is unlikely that BRCA2 directly inhibits nucleolytic degrada-
tion by binding to nascent DNA.marks delineate lagging strands.
t HU in V-C8 (D) and V-C8+BRCA2 (E) cells.
esence of the MRE11 inhibitor mirin.
inst MRE11 or control (shLuc) with or without HU. Western blot inset shows the
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Figure 3. KU70 and RAD54 Deficiency Do Not Affect the Stability of Nascent Strands at Stalled Replication Forks
(A and B) IdU tracts in Ku70/ (A) and Rad54/ (B) mES cells with or without HU. Inset, cumulative distributions.V-C8 cells stably expressing a peptide consisting of one BRC
repeat fused to the large subunit of the ssDNA-binding protein
RPA (BRC3-RPA) (Figure 4A) are proficient in HDR (Saeki et al.,
2006), suggesting that the main function of BRCA2 in HDR is
to deliver RAD51 to ssDNA. These cells, however, exhibit shorter
nascent IdU tract lengths when replication is stalled with HU
(6.35 and 8.81 mm with and without HU, respectively, p <
0.0001) (Figure 4C and Figure S3C). Although the degradation
is not as extensive as with V-C8 cells (Figure 1B), these results
suggest that the delivery of RAD51 to ssDNA is not sufficient
to protect stalled forks.
Highly Conserved BRCA2 C-ter RAD51 Interaction
Site Is Essential for Replication Fork Stability
but Dispensable for HDR
BRCA2 interacts with RAD51 through both the BRC repeats and
the C-ter. Although RAD51 loading through the BRC repeats
does not seem to be sufficient for the protection of stalled forks,
the conserved C-ter appears to provide an essential function,
given our results with the Brca2lex1/lex2 cells (Figure 1C). The
C-ter binds RAD51 differently than the BRC repeats in that it
interacts with RAD51 oligomers and stabilizes RAD51 filaments
(Davies and Pellegrini, 2007; Esashi et al., 2007). Moreover, the
RAD51 binding site at the C-ter contains a cyclin dependent
kinase (CDK) phosphorylation consensus sequence that is
conserved throughout vertebrates (Esashi et al., 2005) as well
as some invertebrates (Figure 5A and Figure S4A); phosphoryla-
tion by CDK at this site (S3291) abrogates the C-ter-RAD51 inter-
action (Davies and Pellegrini, 2007; Esashi et al., 2005), thereby
promoting RAD51 filament disassembly that in turn promotes
entry into mitosis (Ayoub et al., 2009).
To further investigate the function of the C-ter, we utilized V-C8
cells stably expressing full-length BRCA2 containing the S3291A
mutation that, like phosphorylation, disrupts RAD51 binding at534 Cell 145, 529–542, May 13, 2011 ª2011 Elsevier Inc.this site (Davies and Pellegrini, 2007; Esashi et al., 2005). As
with the Brca2lex1/lex2 cells, IdU tracts shorten with HU (5.59
and 10.03 mm with and without HU, respectively, p < 0.0001)
(Figure 5B and Figure S4B), implicating RAD51 interaction at
the C-ter in the protection of stalled replication forks, perhaps
through the stabilization of RAD51 filaments.
To determine the relationship between the protection of
stalled forks and HDR, we quantified HDR in V-C8+BRCA2
S3291A cells using the DR-GFP reporter, where a DSB intro-
duced by the I-SceI endonuclease followed by HDR leads to
GFP-positive cells (Figure 5C). V-C8 cells are highly defective
in HDR compared with V-C8+BRCA2 cells (25-fold) (Figure 5D)
(Saeki et al., 2006). Importantly, V-C8+BRCA2 S3291A cells are
as efficient for HDR as those expressing wild-type BRCA2. Thus,
although the BRCA2 C-ter RAD51 interaction site is essential for
the protection of stalled replication forks, it is dispensable for
HDR, providing a clear separation of function mutation for the
two processes.
BRCA2 Maintains Nascent Replication Tracts
by Stabilizing RAD51 Filaments
To directly test the involvement of RAD51 in the protection of
stalled forks, we expressed the BRC4 peptide (Saeki et al.,
2006), which suppresses DNA binding of RAD51 and thus per-
turbs RAD51 filaments (Davies et al., 2001; Hashimoto et al.,
2010). Aswith defective BRCA2, expression of the BRC4 peptide
in wild-type mES cells leads to substantially shorter IdU tracts
on HU (3.67 and 6.65 mm with and without HU, respectively,
p < 0.0001) (Figure 5E and Figure S4D). These data indicate
that disruption of RAD51 filaments leads to nascent strand
degradation.
We next asked whether stabilization of filaments could
suppress this degradation. ATP hydrolysis by RAD51 is required
for efficient dissociation from DNA whereas association with
Figure 4. BRCA2 Domain Analysis Reveals Differences between Fork Stabilization and HDR
(A) Graphical sketch of human BRCA2, PIR2, and BRC3-RPA. PALB2-interaction site (bright green bar), BRC repeats (dark green bars), DNA binding domain
(DBD, black bar), C-terminal region (C-ter) with non-BRC RAD51 binding site (red bar). Arrows indicate truncations in V-C8 cells.
(B and C) IdU tracts in V-C8 cells stably expressing the PIR2 (B) or BRC3-RPA (C) peptide with or without HU. See also Figure S3.DNA is unaffected (Benson et al., 1994; van Mameren et al.,
2009). RAD51 K133R, which is devoid of ATPase activity, forms
stable filaments and promotes strand exchange in vitro (Morri-
son et al., 1999) while suppressing turnover or completion of
successful HDR in vivo (Stark et al., 2002). Overexpression of
RAD51 K133R in Brca2lex1/lex2 cells exposed to HU renders IdU
tracts resistant to degradation (7.22 and 6.81 mm with and
without HU, respectively, p = 0.077) (Figure 5F and Figure S4E),
indicating that stabilized RAD51 filaments rescue the protection
of stalled forks and consistent with the requirement for the C-ter
in this process. Expression of BRC4 has no effect in these cells
(Figure 5F and Figure S4E), suggesting that BRCA2 and RAD51
are epistatic for fork protection.
Replication Fork Stalling Leads to MRE11-Dependent
Genomic Instability in BRCA2-Deficient Cells
We next sought to determine the physiological consequences of
replication perturbation in cells that cannot maintain the integrity
of stalled replication forks. Both V-C8 and V-C8+BRCA2 S3291A
cells exhibit elevated spontaneous chromosomal abnormalities
compared to cells with wild-type BRCA2, revealing intrinsic
genomic instability in cells expressing BRCA2 S3291A (Fig-
ure 6A). Exposure to HU substantially increases the average
number of aberrations per metaphase spread in both cell lines,from 0.51 to 1.77 for V-C8 cells and from 0.12 to 0.37 for
V-C8+BRCA2 S3291A cells (Figure 6B). Thus, replication stalling
induces chromosomal aberrations in cells that are defective in
protecting forks from degradation.
Treatment of cells with HU has been reported to lead to DSB
formation after prolonged exposure times, whereas treatment
with HU for a few hours, as performed here, does not cause
such lesions (Hanada et al., 2007; Petermann et al., 2010). Given
that the degradation of forks is not correlated to HDR (Figure 5D),
we sought to further distinguish genomic instability arising from
DSBs from genomic instability arising from degraded forks by
treating cells with colcemid immediately after HU exposure.
As with delayed colcemid treatment, breaks/gaps increase in
V-C8 cells with HU exposure, and triradial/quadriradial chromo-
somes increase even further (Figures 6C and 6E), suggesting
that unprotected replication forks expose potential sites for
aberrant interchromosomal end-joining. Overall, the average
number of chromosomal aberrations per metaphase in V-C8
cells increases from 0.56 to 2.5 with HU (Figure 6D). Similarly,
aberrations increase with HU in V-C8+BRCA2 S3291A cells,
whereas the number of aberrations in cells expressing wild-
type BRCA2 is substantially lower (Figures S5A–S5C). Thus, cells
in which stalled replication forks degrade exhibit greater
genomic instability.Cell 145, 529–542, May 13, 2011 ª2011 Elsevier Inc. 535
Figure 5. Highly Conserved BRCA2 C-ter is Essential in Maintaining Replication Fork Stability by Stabilizing RAD51 Filaments
(A) Blast alignments of BRCA2C-terminal sequences; CDK phosphorylation target motif (SP, red letters); cyclin A recognitionmotif (RxL, blue; similar amino acids
are in italics). See also Figure S4A.
(B) IdU tracts in V-C8+BRCA2 S3291A cells with or without HU.
(C) HDR assay for a DSB using the DR-GFP reporter.
(D) HDR assay in V-C8 and BRCA2 BAC-complemented cells. GFP-positive cells indicate HDR events after I-SceI expression. Error bars indicate standard
deviation; p-value derived from two-tailed Student’s t test.
(E) IdU tracts after BRC4 peptide expression in mES cells with or without HU. pCaggs, empty vector. Western blot inset shows BRC4 transient expression.
(F) IdU tracts after RAD51 K133R or BRC4 expression inBrca2lex1/lex2mES cells with or without HU.Western blot inset showsRAD51 K133R transient expression.
See also Figure S4.
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As the MRE11-inhibitor mirin alleviates degradation of stalled
forks in BRCA2-deficient cells (Figure 2F), we asked whether
inhibition of MRE11 could also alleviate HU-induced chromo-
some aberrations. Both breaks/gaps and radial chromosomes
were reduced in V-C8 cells treated with HU and mirin compared
to HU alone (Figure 6C). Overall, the average number of chromo-
somal aberrations per metaphase decreased >2-fold when
MRE11 nuclease activity was inhibited during fork stalling (1.07
and 2.54 with and without mirin, respectively, p = 0.015) (Fig-
ure 6D). As inhibiting the degradation of stalled replication forks
in BRCA2-deficient cells is associated with reduced numbers of
chromosome aberrations, these data support a relationship
between degradation of stalled replication forks by MRE11 and
genomic instability.Replication Stalling in BRCA2-Deficient Cells Does Not
Reduce Cellular Survival
To investigate long-term effects of stalled replication, cell
survival was examined following exposure to agents that have
differential effects on replication. After continuous exposure to
HU, V-C8 and V-C8+BRCA2 S3291A cells show only modest
sensitivity to HU relative to cells expressing wild-type BRCA2
(Figure 6F), suggesting that fork degradation has little effect on
cell survival. We also pulsed cells under the conditions used in
the DNA fiber experiments and again saw no significant differ-
ence in survival (data not shown). Thus, although chromosomal
aberrations increase, cell survival is not compromised, indicating
that BRCA2 deficiency will be associated with increased muta-
genesis when replication is perturbed.
V-C8 cells are exquisitely sensitive to poly(ADP-ribose)
polymerase (PARP) inhibitors like olaparib (Figure 6G) (Farmer
et al., 2005). By contrast, cells expressing either wild-type
BRCA2 or the S3291A mutant are similarly resistant to this
drug (Figure 6G). Given that PARP inhibition leads to ssDNA
breaks that are converted to DSBs during S phase, efficient
repair of these DSBs is consistent with the BRCA2 S3291A
mutant being proficient at DSB repair by HDR. Supporting
this, similar results were obtained with other agents that require
HDR, i.e., 6-thioguanine and mitomycin C (Figures S5D and
S5E).DISCUSSION
BRCA2 Protects Stalled Replication Forks
by Blocking Degradation
As HDR is important during perturbed DNA replication, it has
been presumed that the key function of BRCA2 in this regard
is to promote repair of collapsed replication forks via HDR (Fig-
ure S6A). We show here that BRCA2 prevents rather than repairs
nucleolytic lesions at stalled forks, revealing a conceptual and
mechanistic difference with consequences for tumorigenesis,
as discussed below. This role for BRCA2 in protecting newly
replicated strands at stalled replication forks from degradation
was unforeseen. Importantly, using a separation of function
BRCA2 mutant, we find that fork protection is distinct from
HDR, yet critical in maintaining genomic stability when DNA
replication is stressed with HU.Requirement for Evolutionary Conserved
BRCA2 C-ter in Stabilizing RAD51 Filaments
during Replication Stalling
BRCA2 is crucial for RAD51 filament formation on ssDNA
(Jensen et al., 2010; Moynahan and Jasin, 2010). To this end,
BRCA2 binds monomeric RAD51 via its BRC motifs (Davies
and Pellegrini, 2007), directing RAD51 onto ssDNA while pre-
venting RAD51 from nucleating filaments on dsDNA (Jensen
et al., 2010). We show here that fork protection specifically
requires a RAD51 interaction site at the BRCA2 C terminus
(C-ter), which differs from BRC motifs in that it stabilizes
RAD51 filaments by binding to the interface of two adjacent
RAD51 molecules (Davies and Pellegrini, 2007; Esashi et al.,
2007). Our results extend the recent observation of a role for
RAD51 in protecting nascent strands from degradation (Hashi-
moto et al., 2010) and provide critical mechanistic insight.
Specifically, we show that RAD51 filaments stabilized with an
ATPase-defective RAD51 reverse the degradation of stalled
forks in a BRCA2mutant. Conversely, conditions that destabilize
RAD51 filaments, such as BRC4 expression or BRCA2 C-ter
mutation, render cells susceptible to fork degradation. RAD51
filament dissociation is triggered by ATP hydrolysis in conjunc-
tion with the release of tension stored within the extended DNA
strand of the nucleoprotein filament (van Mameren et al.,
2009). As replication fork structures exert force on DNA (Postow
et al., 2001), theymay require greater efforts at filament stabiliza-
tion than frank DSBs. As the C-ter site is highly conserved
throughout vertebrates and even invertebrates, it may reflect
an evolutionarily conserved mechanism for the protection of
stalled forks.
MRE11 Nuclease and Stalled Replication
Fork Degradation
Our results imply that fork degradation occurs 30-50 on leading
strands and 50-30 on lagging strands promoted by MRE11. The
intrinsic nucleolytic activities of MRE11 (Williams et al., 2008)
may be sufficient to promote fork degradation; alternatively,
MRE11 could act in conjunction with other nucleases. For
example, as part of the MRN complex MRE11 could initiate
degradation of nascent lagging strands, whereas other 50-30
nucleases (EXO1, CtIP) could be involved in extensive degrada-
tion, akin to DNA end resection (Mimitou and Symington, 2009).
Additionally, MRE11 could interact with other nucleases for
leading strand degradation, for example, WRN, which
possesses 30-50 exonuclease activity that is stimulated by
MRE11 (Cheng et al., 2004) and that is recruited byMRN to repli-
cation foci on HU treatment (Franchitto and Pichierri, 2004).
Although Exo1 degrades stalled replication forks that reverse
into ‘‘chicken foot’’ structures in checkpoint defective yeast cells
(Cotta-Ramusino et al., 2005), checkpoint activation has been
reported to be intact in BRCA2-deficient cells (Lomonosov
et al., 2003). Given that another consequence of MRE11 inhibi-
tion is disruption of ATM signaling (Dupre et al., 2008), it is
possible that EXO1 promotes resection of lagging strands in
these checkpoint-compromised cells. Such strand selective
degradation would create ssDNA stretches not immediately
suitable for aberrant NHEJ, which could explain the observed
decrease in HU-induced radial structures when MRE11 isCell 145, 529–542, May 13, 2011 ª2011 Elsevier Inc. 537
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Figure 7. Model for HDR-Independent Role of BRCA2 during DNA Replication
A replication fork can stall for various reasons, including insufficient pools of nucleotides as from HU. BRCA2 (pink circle) stabilizes RAD51 filaments (blue circles)
on stalled replication forks, thereby preventing fork reversal promoted by positive supercoils ahead of the fork (gray circles). Alternatively, stabilized filaments
directly protect a reversed fork. Once the replication stall is removed, genome duplication can proceed until completed. BRCA2 is then no longer required for fork
protection, such that CDK phosphorylates the BRCA2C-ter, allowing residual RAD51 filaments to dissociate to promote progression intoMphase. Importantly, in
the absence of BRCA2, nascent strands of the stalled fork are unprotected and degraded by MRE11 (yellow pacman), leading to chromosomal instability.
See also Figure S6.inhibited. Whether directly or indirectly, MRE11 promotes dele-
terious strand processing at stalled forks in BRCA2-deficient
cells.
BRCA2-Mediated Fork Protection
Given our data, we propose a model in which BRCA2 prevents
nucleolytic attack of stalled replication fork intermediates that
have reversed to form a chicken foot structure (Figure 7,
reversed fork). Fork reversal regresses the stalling site back
into the duplex region where, in the case of a template lesion,
it is accessible for nucleotide or base excision repair. If the
leading strand has progressed farther than the lagging strand,
fork reversal will result in a 30 ssDNA overhang, which can be
extended by additional end-resection to support RAD51 filament
assembly. Alternatively, blocked leading strands with continued
lagging strand synthesis produces 50 protruding ends on fork
reversal that are extendable by MRE11-promoted processingFigure 6. Replication Fork Stalling Leads to Genomic Instability in BRC
(A and B) Chromosomal aberrations with or without HU treatment in the indicated V
of metaphase spreads with the indicated aberrations (A) and the number of ch
two-tailed Student’s t test.
(C and D) Chromosomal aberrations with or without HU in V-C8 cells in the presen
experimental design. The% of metaphase spreads with the indicated aberrations
(E) Chromosomal aberrations in V-C8 cells exposed toHU include breaks (black ar
other translocation (blue arrow).
(F and G) Survival of indicated V-C8 cell lines on continuous exposure to HU (F
Figure S5.(Figure S6B). As BRCA2 binds to 30 and 50 tailed DNA substrates,
promotes RAD51 filaments on both 30 and 50 ssDNA overhangs
(Mazloum and Holloman, 2009), and blocks RAD51 nucleation
on dsDNA (Jensen et al., 2010), BRCA2, by stabilizing RAD51
filaments, can probably limit both 30-50 degradation of the
reversed leading strand (Figure 7, broken blue arrow) as well
as excessive 50-30 processing of the lagging strand (Figure 7,
broken gray bar).
Continued unwinding at a stalled fork can result in positive
supercoiling of the parental strands upfront of the fork, providing
sufficient energy for fork reversal in the absence of the replisome
(Postow et al., 2001). However, in yeast extensive fork reversal is
observed as a consequence of defective checkpoint signaling,
such that reversed forks are considered pathological structures
that are rare in wild-type backgrounds (Foiani et al., 2000; Sogo
et al., 2002). Besides or in addition to protection of reversed
forks, therefore, BRCA2 could stabilize the replisome and theA2-Deficient Cells
-C8 cell lines. Sketch above the graphs delineates experimental design. The%
romosome aberrations per metaphase (B) are plotted. p value derived from
ce or absence of the MRE11-inhibitor mirin. Sketch above the graph delineates
(C) and the number of chromosome aberrations per metaphase (D) are plotted.
rowheads), gaps (red arrowhead), triradials, quadradials (green arrowhead) and
) and the PARP-inhibitor olaparib (G). Error bars represent the SEM. See also
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stalled fork structure itself to prevent formation of reversed forks,
which could then be degraded (Figure 7). For template lesions,
RAD51-covered forks could then recruit translesion synthesis
polymerases, similar to what is thought to occur in Escherichia
coli when error-free repair is not possible (Schlacher and
Goodman, 2007).
The protective role of BRCA2 is independent of HDR, but
we propose that it could relate to the licensing of cell-cycle
progression (Figure 7). In the presence of stalled replication
forks, CHK1-mediated inhibition of CDK prevents phosphoryla-
tion of BRCA2 C-ter. Eventually when dNTP pools are restored
or lesions are removed, replication can restart, through fork
regression or other means. Once the genome is fully duplicated
and stable RAD51 filaments are no longer required to protect the
nascent DNA strands, CDK phosphorylates the BRCA2 C-ter,
thus promoting RAD51 disassembly, which has been shown to
promote entry into mitosis (Ayoub et al., 2009).
Recovery after Replication Stalling
in BRCA2-Deficient Cells
We did not observe any obvious defect in replication recovery or
initiation of new replication tracts with disruption of either BRCA2
(Figure 1E and Figure S1D) or RAD51 in rodent cells (Figure S4F),
seemingly contradicting a previous report implicating RAD51 in
replication restart in a human cell line (Petermann et al., 2010).
Formally, this could be due to differences in cell systems, as
replication in rodent cells does not appear to be as stringently
inhibited by HU as in human cells, and indeed in BRCA2-defi-
cient human cells we did observe a small, although insignificant,
decrease in forks that were dual-labeled after exposure to HU
(Figure S1E).
On further examination, however, we provide evidence that
fork uncoupling increases with HU in BRCA2-deficient cells, ex-
tending recent findings implicating RAD51 in this process (Hashi-
moto et al., 2010). The reported decrease in apparent replication
restart in RAD51-depleted human cells (Petermann et al., 2010),
therefore, could also reflect increased uncoupling of leading and
lagging strands when monitoring progression of one strand only.
Importantly, inhibition of MRE11 does not affect fork uncoupling
(Hashimoto et al., 2010), whereas we observe fewer aberrations
by inhibiting MRE11. Therefore, fork uncoupling, which is a
frequent event in wild-type cells (Sogo et al., 2002), may have
minor consequences on chromosomal stability compared to
nascent strand degradation described here.
Unprotected Replication Forks Are a Source
of Chromosomal Instability
We observe that although replication stress does not substan-
tially compromise survival of BRCA2-deficient cells, it does
lead to gross chromosome aberrations, including breaks and
radial chromosome structures. The lesions created by degrada-
tion are structurally distinct from bona fide DSBs such as created
by inhibition of PARP, which causes severe cell death in HDR
deficient cells. As replication stress occurs with oncogene
activation (Negrini et al., 2010), our results imply that BRCA2-
deficient cells are likely particularly vulnerable to oncogene
activation for the generation of chromosome aberrations leading
to tumorigenesis. Whether cells die or undergo mutagenesis has540 Cell 145, 529–542, May 13, 2011 ª2011 Elsevier Inc.important consequences with regard to tumorigenesis. For
example, intestinal BRCA2 deficiency does not promote tumor
formation due to elimination of cells by apoptosis (Hay and
Clarke, 2005). By contrast, survival of cells with acquired muta-
tions, such as those arising during replication stalling as shown
here, encourages initiation and progression of tumorigenesis.
In support of fork degradation-dependent, HDR-independent
mechanisms of tumorigenesis, mutations affecting the BRCA2
C-ter CDK phosphorylation site are found in individuals affected
with breast cancer (Esashi et al., 2005).
We propose that the HDR-independent role of BRCA2 in
preventing the degradation of stalled replication forks and the
resultant chromosome rearrangements has important implica-
tions for therapy. BRCA2 mutants that are defective in maintain-
ing fork stability but remain proficient for HDR will be insensitive
to chemotherapeutics such as PARP inhibitors, which specifi-
cally exploit the defect in repair of DSBs. Moreover, chemother-
apeutics that elicit transient replication stress may not only be
ineffective in killing cells but also induce mutagenesis and
genomic instability. Collectively, these results and concepts
change our understanding of BRCA2 and MRE11 during replica-
tion and repair.
EXPERIMENTAL PROCEDURES
Cell Lines, Chemicals, and Drugs
Hamster cells, including V-C8 (Wiegant et al., 2006), V-C8+BRC3-RPA (Saeki
et al., 2006), V-C8+PIR2, and V-C8 cells complemented with human BACs
(V-C8+BRCA2 and V-C8+BRCA S3291A, see Supplemental Information),
were grown in DMEM with 10% FBS. CAPAN-1 and CAPAN-1 C2-14 (Sakai
et al., 2008) were grown in RPMI 1640 with 20% FBS and 1 mM sodium pyru-
vate. Brca2lex1/lex2 (Morimatsu et al., 1998), Ku70/ (Gu et al., 1997), and
Rad54/ (Essers et al., 1997) mES cells were cultured in standard ES media.
Brca2lex1/lex2 cells express a BRCA2 peptide deleted for the C-ter200 amino
acids encoded by exon 27. Except for olaparib (Selleck Chemicals), all chem-
icals were from Sigma-Aldrich.
DNA Fiber Assay
Cells were labeled with IdU (50 mM), followed by exposure to hydroxyurea
(4 mM), gemcitabine (1 mM), or untreated media and chased with CldU
(50 mM). DNA fibers were essentially spread as described (Jackson and
Pombo, 1998) before standard detection of IdU and CldU tracts (primaries:
a-IdU, a-BrdU from BD Biosciences; a-CldU, a-BrdU from Novus Biologicals
and secondaries: Alexa Fluors 488 and 555, respectively, from Invitrogen).
Fibers were imaged (Olympus BX60 microscope) and analyzed using ImageJ
software. Statistics were calculated using Prism software (see Table S1).
The rate for nascent tract replication was estimated using the conversion of
2.59 kb/mm (Jackson and Pombo, 1998).
Cell Transfections, Survival Assays, and Metaphase Spreads
For HDR assays, 53 106 V-C8 cells or derivatives were transfected with 50 mg
pCBASce, the I-SceI expression vector, by electroporation at 280 V, 1000 mF
(Saeki et al., 2006), and 48 hr later, GFP-positive cells were quantified
using a FACScan and CellQuest software (Becton Dickinson). For other
assays, 5 3 106 or 10 3 106 mES cells were transfected with expression
vectors for BRC4 (BRCA2 aa 1511–1578) (Saeki et al., 2006), RAD51K133R
(Stark et al., 2002), and MRE11 shRNA (50ACAGGAGAAGAGATCAACT in
pSuper) by electroporation at 250V, 950 mF. Expression was assessed 36 hr
after transfection with antibodies against Flag (Sigma), RAD51 (Santa Cruz),
or MRE11 (Abcam).
For survival assays, 3000 cells were seeded in a 24-well plate the day before
continuous treatment with the indicated drugs. The number of viable cells was
determined when confluence reached 80% for the untreated cells using Cell
Titer 96 AQeous One Solution Cell Proliferation Assay (Promega). For meta-
phase spreads, 2 3 105 cells were seeded the day before HU (4 mM) and
treated with colcemid (0.1 mg/ml, GIBCO), as indicated. For metaphase
spreads, cells were swollen with 0.075 M KCL (12 min, 37C), fixed with
methanol/acetic acid (3:1), dropped onto a microscope slide, stained with
5% Giemsa, and mounted with Cytoseal 60 (Fisher Scientific) before imaging
with an Olympus BX60 microscope.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
six figures, and one table and can be found with this article online at
doi:10.1016/j.cell.2011.03.041.
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